Exelixis, Inc. (NASDAQ:EXEL)
| Market Cap | $16.25B+53.0% |
| Revenue (ttm) | $2.50B+9.1% |
| Net Income | $885.14M+30.6% |
| EPS | $3.34+40.9% |
| Shares Out | 251.36M |
| PE Ratio | 18.73 |
| Forward PE | 15.35 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,194,294 |
| Open | $65.90 |
| Previous Close | $65.83 |
| Day's Range | $64.44 - $66.94 |
| 52-Week Range | $39.71 - $73.69 |
| Beta | 0.42 |
| Analysts | Hold |
| Price Target | $54.20(-16.14%) |
| Earnings Date | Feb 9, 2027 |
About EXEL
Exelixis, Inc. operates as a biotechnology firm dedicated to combating cancer, primarily focusing on the identification, advancement, and marketing of novel oncological treatments within the United States. Its portfolio of commercially available therapeutics includes CABOMETYX tablets, prescribed for individuals with advanced renal cell carcinoma who have previously undergone anti-angiogenic treatment, and COMETRIQ capsules, utilized for managing progressive and metastatic medullary thyroid cancer. Both CABOMETYX and COMETRIQ originate from cabozantinib, a compound that inhibits several tyrosine kinases such as MET, AXL, RET, and VEGF receptors. Additionally, Exelixis offers COTELLIC, an MEK inhibitor employed in combination therapies for advanced melanoma, and MINNEBRO, an orally administered, non-steroidal selective mineralocorticoid receptor blocker, approved for hypertension treatment in Japan. The company's developmental pipeline features several promising candidates, such as XL092, an oral tyrosine kinase inhibitor designed to target VEGF receptors, MET, AXL, MER, and other kinases crucial for cancer proliferation; XB002, an antibody-drug conjugate containing a human monoclonal antibody against tissue factor (TF), intended for advanced solid tumors and non-Hodgkin's lymphoma; and XL102, an orally available cyclin-dependent kinase 7 (CDK7) inhibitor being developed for advanced or metastatic solid tumors. Exelixis, Inc. maintains extensive research partnerships and licensing arrangements with numerous pharmaceutical and biotechnology entities, including Ipsen Pharma SAS, Takeda Pharmaceutical Company Ltd., F. Hoffmann-La Roche Ltd., Redwood Bioscience, Inc., R.P. Scherer Technologies, LLC, Catalent Pharma Solutions, Inc., NBE Therapeutics AG, Aurigene Discovery Technologies Limited, Iconic Therapeutics, Inc., Invenra, Inc., StemSynergy Therapeutics, Inc., Genentech, Inc., Bristol-Myers Squibb Company, and Daiichi Sankyo Company, Limited. Established in 1994, the company originally operated as Exelixis Pharmaceuticals, Inc. before rebranding to Exelixis, Inc. in February 2000. Its corporate headquarters are located in Alameda, California.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
Analyst consensus
8 firms rating EXEL in the last 3 months, one vote each. Issuer-paid research is not counted.
Next catalysts
- Feb 9, 2027Earnings report
$EXEL stock is featured in our Congress Trading, and Insider Trades datasets.
→ All Stock ListsCongress Trading
Recent trades of EXEL by members of U.S. Congress
| Donna ShalalaHouse | Sale$1.00K – $15.00K | Jun 4, 2019 |
| Donna ShalalaHouse | Sale$1.00K – $15.00K | Apr 16, 2019 |
| Donna ShalalaHouse | Purchase$1.00K – $15.00K | Feb 6, 2019 |
| Donna ShalalaHouse | Purchase$1.00K – $15.00K | Jan 9, 2019 |
Recently reported changes in EXEL holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by EXEL's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
EXEL Estimated quarterly lobbying spending
Source: U.S. Senate LDA
EXEL Revenue by Segment or Geography
| Gross product revenues | $853.72M | 54.35% |
| Net product revenues | $604.92M | 38.51% |
| License revenues | $58.41M | 3.72% |
| Collaboration revenues | $53.77M | 3.42% |
As of: Q4 2026 (Oct 2, 2026) · Source: SEC EDGAR (10-Q)
U.S. Patents
New EXEL patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to EXEL from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in EXEL
| IJHiShares Core S&P Mid-Cap ETF | $577.01M |
| VTIVanguard Morningstar Total Stock Market ETF | $409.93M |
| VBVanguard Morningstar Small-Cap ETF | $366.22M |
| XMHQInvesco S&P MidCap Quality ETF | $205.78M |
| VBKVanguard Morningstar Small-Cap Growth ETF | $204.84M |
| VXFVanguard Extended Market ETF | $195.01M |
Estimated from each fund’s disclosed top holdings × AUM
Bull Case vs Bear Case
AI-generated from EXEL’s recent data — informational, not investment advice
What’s Behind the Score
News check: Pipeline progress and FDA decision catalysts dominate coverage; mixed valuation opinions offset by concrete clinical developments and business momentum.
Recent Insider Activity
Frequently Asked Questions
ETFs that hold this stock
| BOUT | CapForce IBD Breakout Opportunities ETF | 3.90% |
| FBT | First Trust NYSE Arca Biotechnology Index Fund | 3.76% |
| XMHQ | Invesco S&P MidCap Quality ETF | 3.76% |
| CANC | Tema Oncology ETF | 3.74% |
| IDNA | iShares Genomics Immunology and Healthcare ETF | 3.74% |
| NEWZ | StockSnips AI-Powered Sentiment US All Cap ETF | 3.71% |
| MCOW | Pacer Funds Trust - Pacer S&P MidCap 400 Quality FCF Aristocrats ETF | 3.71% |
| SAWG | AAM Sawgrass US Large Cap Quality Growth ETF | 3.48% |
| GLRY | Inspire Growth ETF | 3.41% |
| ASCE | Allspring SMID Core ETF | 3.39% |
| PBE | Invesco Biotechnology & Genome ETF | 3.34% |
| ACTS | FIS Tactical Equity ETF | 3.33% |
Weight is the stock’s share of each fund’s holdings.
